Market
What will be the primary therapeutic area for Gilead's STAT6 drug by the end of 2025?
2
Resolution / Starting Odds
Dermatology • 25%
Rheumatology • 25%
Gastroenterology • 25%
Other • 25%
Official announcements from Gilead Sciences or LEO Pharma
Story
Gilead Sciences Partners with LEO Pharma, Paying $250M for Oral Drug Targeting STAT6 in Inflammatory Diseases
Jan 11, 2025, 05:03 PM
Gilead Sciences has entered into a strategic partnership with LEO Pharma, focusing on the development of an oral drug targeting STAT6, which has potential applications in treating various inflammatory diseases. As part of the agreement, Gilead will pay LEO Pharma $250 million upfront to license the drug. This collaboration aims to accelerate the development of the STAT6 program, which is expected to address unmet medical needs in the field of inflammatory diseases.
View original story
Similar markets
Neurological disorders • 25%
Other • 25%
Infectious diseases • 25%
Cancer • 25%
None of the above • 25%
Positive Phase 1 results • 25%
Phase 2 initiation • 25%
FDA Fast Track designation • 25%
Yes • 50%
No • 50%
20% to 40% • 25%
More than 60% • 25%
Less than 20% • 25%
40% to 60% • 25%
European Union • 25%
None • 25%
China • 25%
United States • 25%
Drug C • 25%
Drug A • 25%
None • 25%
Drug B • 25%
Vaccines • 25%
Other • 25%
Respiratory • 25%
Oncology • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Casgevy leads • 33%
Reni-cel leads • 33%
BEAM-101 leads • 33%
Novel biologics • 25%
New molecular entities • 25%
Other • 25%
Biparatopic antibodies • 25%
Another acquisition in oncology • 25%
Focus on internal development • 25%
Other strategic move • 25%
Partnership with another biotech • 25%
